Clinical features and long term outcome of 102 treated autoimmune hepatitis patients

Hepatitis Monthly

Volumn 12, Issue 2, 2012, Pages 92-99

  Malekzadeh, Zinab ^a,b   Haghazali, Sepideh ^a   Sepanlou, Sadaf G ^a   Vahedi, Homayoon ^a,b   Merat, Shahin ^a,b   Sotoudeh, Masoud ^a,b,c   Nasseri Moghaddam, Siavosh ^a,b   Malekzadeh, Reza ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Sasan Alborz Research Institute   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmune; Chronic; Hepatitis; Iran; Liver cirrhosis; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CALCIUM; COLECALCIFEROL; CREATININE; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ACNE; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BONE PAIN; CERULOPLASMIN BLOOD LEVEL; CHILD; DEATH; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GINGIVITIS; HIRSUTISM; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRICHOSIS; IRAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LEUKOPENIA; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOON FACE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTHROMBIN TIME; RELAPSE; REMISSION; SCHOOL CHILD; SEPSIS; SIDE EFFECT; STRIA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

EID: 84858166058     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.808     Document Type: Article

References (26)

1. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis. 1984;4 (1):1-12.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354 (1):54-66.
3. Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005; 25 (1): 63-71.
4. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125(7):588-598.
5. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993; 18 (4): 998-1005.
6. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31 (5): 929-938.
7. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis. 2002; 6 (3): 685-705.
8. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001; 39 (5): 339-341, 44-8.
9. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110 (3): 848-857.
10. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N, Tavangar SM, Sohrabpour AA, et al. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med. 2004; 117 (2): 125-129.
11. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005; 50 (3): 547-551.
12. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol. 2001; 32 (5): 428-430.
13. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997; 127 (11): 981-985.
14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22 (6): 696-699.
15. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010; 139 (1): 58-72 e4.
16. Omagari K, Kinoshita H, Kato Y, Nakata K, Kanematsu T, Kusumoto Y, et al. Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan. J Gastroenterol. 1999; 34 (2): 221-226.
17. Amarapurkar DN, Patel ND. Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol. 2007; 22 (12): 2112-2117.
18. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007; 1 (1): 129-143.
19. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001; 46 (6): 1321-1327.
20. Nasseri-Moghaddam S, Karimian S, Khashayar P. Cyclosporine A versus Prednisolone for Induction of Remission in Autoimmune Hepatitis: A Randomized Controlled Trial. Hepatology. 2009; 50 (s4): 377A.
21. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004; 38 (9): 805-809.
22. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005; 25 (4): 723-737.
23. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoim mune hepatitis. Gastroenterology. 2010;139 (4): 1198-1206.
24. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983; 3 (5): 685-689.
25. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007; 102 (5): 1005-1012.
26. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007; 27 (4): 507-515.